A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Inarigivir soproxil (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.
- 20 Jun 2018 Treatment arms has been changed from 3 to 4. Planned patient number has increased.
- 20 Jun 2018 Planned number of patients changed from 70 to 90.